Chan Zuckerberg initiative joins Scale Bio’s ‘100 Million Cell Challenge’ to accelerate single cell genomics research

In an­nounc­ing plans on Mon­day to pay up to $95 mil­lion for C2i Ge­nomics, Ve­r­a­cyte is bet­ting that it will ex­pand fur­ther along the can­cer

SAN FRANCISCO — Almost half of patients with untreated cisplatin-ineligible advanced urothelial carcinoma responded to the combination of pembrolizumab (Keytruda) and cabozantinib (Cabometyx), but that